RIGI and cancer: Previous studies have shown that treatment with RIG-I agonists induces direct cancer cell death or cancer immunogenic cell death that is mainly mediated by immune cells, including DCs, NK cells, and CD8+ T cells (Poeck et al., 2008; Besch et al., 2009; Chiappinelli et al., 2015; Roulois et al., 2015; Yu et al., 2016).